Your browser doesn't support javascript.
loading
Associations between elevated depressive symptoms and substance use, prescription opioid misuse, overdose history, pain, and general health among community pharmacy patients prescribed opioids.
Brown, Jennifer L; Cochran, Gerald; Bryan, M Aryana; Charron, Elizabeth; Winhusen, T John.
Affiliation
  • Brown JL; Department of Psychology, University of Cincinnati, Cincinnati, Ohio, USA.
  • Cochran G; Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Bryan MA; Center for Addiction Research, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Charron E; Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
  • Winhusen TJ; Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
Subst Abus ; 43(1): 1110-1115, 2022.
Article de En | MEDLINE | ID: mdl-35499399
ABSTRACT

Background:

Individuals with pain prescribed opioids experience high rates of comorbid depression. The aim of this study was to characterize pain, substance use, and health status as a function of depressive symptom level in individuals filling an opioid prescription at a community pharmacy.

Methods:

Participants (N = 1268) filling an opioid prescription enrolled in a study validating a prescription drug monitoring metric completed an online survey assessing sociodemographics, depressive symptoms, substance use, prescription opioid misuse, overdose history, general health, and pain severity and interference.

Results:

Approximately one-fifth (19.3%) had a positive depression screen result. In covariate-adjusted logistic regression analyses, individuals with a positive depression screen result were more likely to have moderate/high substance use risk scores for prescription opioids (adjusted odds ratio [AOR] = 2.06; 95% confidence interval [CI], 1.51-2.79); street opioids (AOR = 7.18; 95% CI, 2.57-20.01); cannabis (AOR = 2.00; 95% CI, 1.34-3.00); cocaine (AOR = 3.46; 95% CI, 1.46-8.22); tobacco (AOR = 1.59; 95% CI, 1.18-2.15); methamphetamine (AOR = 7.59; 95% CI, 2.58-22.35); prescription stimulants (AOR = 2.95; 95% CI, 1.59-5.49); and sedatives (AOR = 3.41; 95% CI, 2.43-4.79). Individuals with a positive depression screen were more likely to misuse prescription opioids (AOR = 3.46; 95% CI, 2.33-5.15), experience a prior overdose (AOR = 2.69; 95% CI, 1.76-4.11), report poorer general health (AOR = 0.25, 95% CI, 0.18-0.35), and report moderate/severe pain severity (AOR = 4.36, 95% CI, 2.80-6.77) and interference (AOR = 6.47, 95% CI, 4.08-10.26).

Conclusions:

Individuals prescribed opioids with heightened depression were more likely to report other substance use, prescription opioid misuse, prior overdose, greater pain, and poorer health.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Pharmacies / Mauvais usage des médicaments prescrits / Troubles liés aux opiacés Type d'étude: Diagnostic_studies / Risk_factors_studies Aspects: Patient_preference Limites: Humans Langue: En Journal: Subst Abus Sujet du journal: TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Année: 2022 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Pharmacies / Mauvais usage des médicaments prescrits / Troubles liés aux opiacés Type d'étude: Diagnostic_studies / Risk_factors_studies Aspects: Patient_preference Limites: Humans Langue: En Journal: Subst Abus Sujet du journal: TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Année: 2022 Type de document: Article Pays d'affiliation: États-Unis d'Amérique